These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37414719)

  • 1. Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.
    González-López TJ; Provan D; Bárez A; Bernardo-Gutiérrez A; Bernat S; Martínez-Carballeira D; Jarque-Ramos I; Soto I; Jiménez-Bárcenas R; Fernández-Fuertes F
    Blood Rev; 2023 Sep; 61():101112. PubMed ID: 37414719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
    Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
    Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
    Vianelli N; Auteri G; Buccisano F; Carrai V; Baldacci E; Clissa C; Bartoletti D; Giuffrida G; Magro D; Rivolti E; Esposito D; Podda GM; Palandri F
    Ann Hematol; 2022 May; 101(5):963-978. PubMed ID: 35201417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
    Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
    Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current approaches for the diagnosis and management of immune thrombocytopenia.
    Gafter-Gvili A
    Eur J Intern Med; 2023 Feb; 108():18-24. PubMed ID: 36424271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO; Patekar MB; Milunović V
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
    Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
    Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X
    Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.
    Ayad N; Grace RF; Al-Samkari H
    Pediatr Blood Cancer; 2022 Mar; 69(3):e29447. PubMed ID: 34962697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
    Červinek L; Mayer J; Doubek M
    Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and Therapy of Immune thrombocytopenia].
    Matzdorff A; Wörmann B
    Dtsch Med Wochenschr; 2018 Aug; 143(15):1076-1081. PubMed ID: 30060276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics.
    Liebman HA; Pullarkat V
    Hematology Am Soc Hematol Educ Program; 2011; 2011():384-90. PubMed ID: 22160062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
    Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
    Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
    Gudbrandsdottir S; Frederiksen H; Hasselbalch H
    Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
    Makar RS; Zhukov OS; Sahud MA; Kuter DJ
    Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options.
    Mititelu A; Onisâi MC; Roșca A; Vlădăreanu AM
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
    Mingot-Castellano ME; Caparrós IS; Fernández F; Perera-Alvarez MDM; Jimenez-Bárcenas R; Casaus García A; González-Silva M; Yera-Cobo M; Nieto-Hernandez MM; Rodríguez-Fernandez MJ; Díaz-Canales D
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):374-380. PubMed ID: 29738335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.